Center for Molecular Medicine at Karolinska Institute in Stockholm, Sweden

Tabassom Mohajershojai is a postdoctoral researcher at the Center for Molecular Medicine at Karolinska Institute in Stockholm, Sweden. Her research focuses on integrating targeted radionuclide therapy (TRT) with cancer immunotherapy (IT), particularly in cancers expressing carcinoembryonic antigen (CEA) and CD44v6.

Her postgraduate work provided preclinical evidence for enhanced anti-tumor efficacy through immune modulation by radioconjugates. Following her veterinary medical training and PhD, she joined a multidisciplinary team at Karolinska Institute. There, she is involved in the generation and use of transgenic mouse models to better understand the tumor immune microenvironment and to support the translation of TRT–IT combinations into the clinic.

Her ongoing research includes exploring the immune landscape shaped by TRT and the development of synergistic therapeutic strategies that bridge molecular imaging, immunology, and translational oncology. She is a member of the Swedish Society for Immunology and actively contributes to international scientific collaborations in cancer research.

Dr. Mohajershojai advances precision medicine by combining therapy biomarkers and functional immunology with innovative therapeutic approaches.